Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pejman Ghanouni

Diagnostic Radiology Stanford, CA Medical Doctor

NPI 1124214028 CMS profile 651686

300 Pasteur Dr, Stanford, CA 94305

Open in the dashboard

General payments

$60,834

145 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$665,037 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Pejman Ghanouni of Stanford, CA is reported in the CMS Open Payments database as having received $60,834 across 145 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $665,037 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,997 32
2024 General $8,955 25
2023 General $14,557 35
2022 General $4,879 19
2021 General $477 20
2020 General $4,360 7
2019 General $13,609 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pejman Ghanouni
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Pejman Ghanouni were reported at $13,997. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Pejman Ghanouni Diagnostic Radiology median Middle half National median
2019 $13,609 $108 $29–$318 $163
2020 $4,360 $65 $21–$252 $114
2021 $477 $92 $24–$292 $132
2022 $4,879 $104 $29–$294 $149
2023 $14,557 $110 $29–$337 $160
2024 $8,955 $113 $30–$356 $164
2025 $13,997 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Profound Medical Corp. $30,671 23 payments
  2. InSightec,Inc $21,664 19 payments
  3. Boston Scientific Corporation $2,790 90 payments
  4. Turing Medical Technologies $2,275 1 payment
  5. InSightec,LTD $1,427 2 payments
  6. Histosonics, Inc. $1,197 2 payments
  7. Siemens Medical Solutions USA, Inc. $809 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,975 8 payments
  2. Travel and Lodging $22,972 21 payments
  3. Honoraria $8,800 3 payments
  4. Food and Beverage $5,087 113 payments
Products named General payments · program years 2019–2025
  1. Tulsa-Pro Device $19,086 9 payments
  2. Tulsa-Pro Oncology $11,558 13 payments
  3. EXABLATE $5,445 10 payments
  4. MAGNETOM Vida $809 8 payments
  5. ICEfx Cryoablation System $700 22 payments
  6. Visual-ICE MRI Cryoablation Console $561 18 payments
  7. GENERAL - IO ABLATION Ablation $219 3 payments
  8. VISUAL ICE $207 9 payments
  9. General - IO Ablation General - IO Ablation_PI $163 5 payments
  10. ACCUSTICK $116 1 payment
  11. Other $412 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

51

Median for Diagnostic Radiology: 24

Drug cost

$771

Median for Diagnostic Radiology: $190

Branded share of claims

47.1%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 13 $338
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 11 $207
Dexamethasone Generic 12 $116
Tamsulosin Hcl Generic 15 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$71,326

Medicare's payments for the services billed

Medicare patients

566

Average age 73

Services billed

888

220 women, 346 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Cancer 41%
Arthritis 38%
Diabetes 34%
Chronic kidney disease 29%
Ischemic heart disease 28%
Osteoporosis 23%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record